Article info

Download PDFPDF

Original research
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

Authors

  1. Correspondence to Dr Heather C Losey; Heather.Losey{at}alkermes.com
View Full Text

Citation

Lopes JE, Fisher JL, Flick HL, et al
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

Publication history

  • Accepted March 24, 2020
  • First published April 21, 2020.
Online issue publication 
April 21, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.